Case study: Discovering Selective VEGFR3 (FLT4) Inhibitor for Solid Tumors

Program co-owned-target ID by analysis of tumor samples from cancer patients done by our partner Oncobox.

Target

VEGFR3 (FLT4)

Chemical space

Enamine REAL 3B

Models we used

B1

Hit rate (<10 μM)

3.6%

Selectivity

45x VEGFR1, 58x VEGFR2 Best hit IC50 1.7 μM

Best hit IC50

1.7 μM

Challenge

Existing VEGFR-targeting cancer drugs are pan-inhibitors Unmet need for a highly selective VEGFR3 inhibitor, which would be a safer (less metastasis, cardiotoxicity) and more efficacious drug for thyroid, kidney, pancreatic, and ovarian cancers (~$10B combined market)

Solution & Impact

BIOPTIC B1 model identified a chemically novel 1.7 uM FLT4 inhibitor which is highly selective against 2 closest targets VEGFR1 (45x) & VEGFR2 (58x).

Thanks for getting in touch.

We’ve received your inquiry and will follow up by email.

Your form wasn’t submitted. Please try again or email office@bioptic.io.

Case study: Discovering Selective VEGFR3 (FLT4) Inhibitor for Solid Tumors

Challenge

Solution & Impact

BIOPTIC B1 Identifies Novel Miro1 ligands for Friedreich's ataxia — Stanford-led Cell Chemical Biology Study

BIOPTIC Agent Hunt Globally — Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence (arXiv, 2026)

BIOPTIC B1 Ultra-High-Throughput Virtual Screening System Discovers LRRK2 Ligands in Vast Chemical Space

Tell us about your project

Tell us about your project

Get report samples

Case study: Discovering Selective VEGFR3 (FLT4) Inhibitor for Solid Tumors

Challenge

Solution & Impact

Related

BIOPTIC B1 Identifies Novel Miro1 ligands for Friedreich's ataxia — Stanford-led Cell Chemical Biology Study

BIOPTIC Agent Hunt Globally — Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence (arXiv, 2026)

BIOPTIC B1 Ultra-High-Throughput Virtual Screening System Discovers LRRK2 Ligands in Vast Chemical Space

Tell us about your project